Alecnib 150 mg is identified on this website as a product containing alectinib, an oral targeted anticancer medicine belonging to the anaplastic lymphoma kinase (ALK) inhibitor class. Alectinib is used for specified patients with ALK-positive non-small cell lung cancer (NSCLC).
This page provides general prescribing-related information about alectinib, including its therapeutic use, dosage principles, administration, warnings, precautions, adverse reactions, and monitoring requirements.
Important product distinction: This page is not an official prescribing information document for Alecnib. The manufacturer, regulatory authorization, dosage form, and approved product-specific instructions for Alecnib have not been independently established here. Where a reference regimen is described, it must not be assumed to apply automatically to every alectinib product or patient.
1. Active Ingredient
- Active ingredient: Alectinib
- Website-listed product: Alecnib
- Stated strength: 150 mg
- Medicine class: Anaplastic lymphoma kinase (ALK) inhibitor
- Therapeutic category: Targeted anticancer medicine
- Route of administration: Oral, subject to confirmation of the specific product formulation
- Reference product: Alecensa
Alectinib is a selective tyrosine kinase inhibitor that blocks abnormal ALK signaling involved in the growth and survival of certain cancer cells.
The stated strength and product identity of Alecnib should be checked against its original packaging and manufacturer documentation.
2. Approved Therapeutic Uses of Reference Alectinib
The United States prescribing information for the reference product Alecensa includes the following indications:
A. Adjuvant treatment of resected ALK-positive NSCLC
Alectinib is indicated for certain adults following surgical removal of ALK-positive NSCLC when the tumor is at least 4 cm or lymph nodes are positive, as established through an appropriate approved diagnostic test.
Adjuvant treatment is given after surgery to reduce the risk of cancer recurrence.
B. Treatment of metastatic ALK-positive NSCLC
Alectinib is indicated for adults with ALK-positive metastatic NSCLC.
Treatment selection requires confirmation of ALK positivity through appropriate diagnostic testing.
Important: These are reference-product indications under United States prescribing information. They do not establish the regulatory authorization or approved indications of Alecnib in any country.
3. Patient Selection
Appropriate patient selection is essential before initiating alectinib.
Healthcare professionals should:
- Confirm the diagnosis of NSCLC.
- Review the patient’s tumor characteristics.
- Confirm ALK positivity using an appropriate validated diagnostic test.
- Assess the disease stage and treatment setting.
- Review previous cancer treatments.
- Evaluate the patient’s medical history.
- Assess potential treatment-related risks.
For the reference product, ALK testing may involve tumor tissue or plasma specimens in the metastatic setting. If plasma testing does not detect an ALK rearrangement, tumor tissue testing should be considered when feasible.
Alectinib should not be prescribed solely because a patient has lung cancer. The relevant molecular alteration must be established.
4. Dosage and Administration
Reference-product dosing only
The United States prescribing information for Alecensa recommends the following adult regimen:
Reference adult dose
600 mg
Twice daily with food
Morning dose
600 mg
Evening dose
600 mg
For the reference 150 mg capsule formulation, each 600 mg dose consists of four capsules.
This is not an individualized prescription or a confirmed Alecnib dosing instruction.
Administration instructions
For the reference Alecensa capsule formulation:
- Take the medicine orally with food.
- Swallow capsules whole.
- Do not open or dissolve the capsule contents.
- Follow the prescribed schedule.
- Do not take an additional dose after vomiting.
- If a dose is missed, take the next dose at its scheduled time.
The specific Alecnib formulation and instructions must be verified before applying these directions.
5. Treatment Duration
The treatment duration for reference alectinib depends on the indication.
| Treatment setting | Reference treatment duration |
|---|---|
| Adjuvant treatment after qualifying surgery | Two years, or until recurrence or unacceptable toxicity |
| Metastatic ALK-positive NSCLC | Until disease progression or unacceptable toxicity |
Treatment duration should be determined by the treating oncologist. Patients should not stop treatment independently.
6. Dose Modification
Dose modifications may be necessary when patients experience certain adverse reactions.
For the reference Alecensa product, the United States prescribing information provides the following dose-reduction schedule:
| Dose level | Reference dose |
|---|---|
| Starting dose | 600 mg twice daily |
| First reduction | 450 mg twice daily |
| Second reduction | 300 mg twice daily |
The reference product should be discontinued if the patient cannot tolerate 300 mg twice daily.
These adjustments are specific to the reference product’s prescribing information. They must not be independently applied to Alecnib.
Reasons for dose modification may include:
- Significant liver enzyme abnormalities.
- Serious lung inflammation.
- Severe kidney impairment.
- Symptomatic bradycardia.
- Significant CPK elevation.
- Hemolytic anemia.
- Severe hypertriglyceridemia.
- Other clinically important adverse reactions.
Only the treating healthcare professional should decide whether to interrupt, reduce, resume, or discontinue treatment.
7. Contraindications
The United States prescribing information for reference Alecensa lists no formal contraindications.
However, this does not mean alectinib is suitable for every patient.
The healthcare professional must evaluate potential risks, medical history, concurrent medicines, pregnancy status, and other relevant clinical factors.
The contraindications and precautions for Alecnib must be checked against its own applicable product documentation.
8. Warnings and Precautions
Alectinib treatment requires careful monitoring because serious adverse reactions may occur.
8.1 Hepatotoxicity
Alectinib can cause liver injury, including severe hepatotoxicity.
Potential signs include:
- Yellowing of the skin or eyes.
- Dark urine.
- Unusual tiredness.
- Abdominal discomfort.
- Abnormal liver function tests.
For the reference product, liver function tests, including ALT, AST, and total bilirubin, are recommended every two weeks during the first three months, then monthly and as clinically indicated.
More frequent testing may be necessary when abnormalities develop.
8.2 Interstitial Lung Disease and Pneumonitis
Alectinib may cause inflammation of lung tissue.
Symptoms requiring prompt medical assessment include:
- New or worsening cough.
- Shortness of breath.
- Difficulty breathing.
- Fever.
- Unexplained respiratory symptoms.
Suspected lung inflammation requires immediate clinical evaluation. Treatment decisions should follow the applicable prescribing information.
8.3 Renal Impairment
Kidney impairment, including severe cases, has been reported during alectinib treatment.
Patients should be monitored for changes in kidney function. Severe renal toxicity may require treatment interruption, dose modification, or permanent discontinuation.
8.4 Bradycardia
Alectinib may cause bradycardia, meaning an abnormally slow heart rate.
Possible symptoms include:
- Dizziness.
- Fainting.
- Unusual tiredness.
- Weakness.
- Light-headedness.
Heart rate and blood pressure should be monitored regularly. Other medicines that can slow the heart rate should also be reviewed.
8.5 Severe Myalgia and CPK Elevation
Alectinib may cause muscle pain and increased creatine phosphokinase levels.
Patients should report unexplained muscle tenderness, weakness, or pain.
For the reference product, CPK testing is recommended every two weeks during the first month and when unexplained muscle symptoms occur.
8.6 Hemolytic Anemia
Hemolytic anemia involves the premature destruction of red blood cells.
Patients may experience unusual fatigue, weakness, pallor, or other symptoms associated with anemia.
Suspected cases require medical assessment and appropriate laboratory testing.
8.7 Hypertriglyceridemia and Pancreatitis
Severe increases in blood triglycerides have been reported with reference alectinib treatment, including cases associated with acute pancreatitis.
The reference prescribing information recommends checking triglyceride levels before treatment and periodically during therapy.
Severe abdominal pain, particularly when accompanied by nausea or vomiting, requires prompt medical assessment.
8.8 Embryo-Fetal Toxicity
Alectinib may cause fetal harm.
Patients who are pregnant or could become pregnant should discuss the risks with their healthcare professional before starting treatment.
For the reference Alecensa product, females of reproductive potential are advised to use effective contraception during treatment and for five weeks after the last dose. Product-specific instructions and individual circumstances must be reviewed by the treating clinician.
9. Adverse Reactions
The most common adverse reactions reported in the pooled clinical safety population for reference Alecensa included:
| Adverse reaction | Reported incidence |
|---|---|
| Hepatotoxicity | 41% |
| Constipation | 39% |
| Fatigue | 36% |
| Myalgia | 31% |
| Edema | 29% |
| Rash | 23% |
| Cough | 21% |
These figures describe the reference product’s pooled clinical trial population and should not be interpreted as the expected incidence for every patient or Alecnib product.
Other clinically important adverse reactions include bradycardia, renal impairment, CPK elevation, hemolytic anemia, lung inflammation, and severe hypertriglyceridemia.
10. Drug Interactions
Alectinib is metabolized primarily through CYP3A4-related pathways. Other medicines may affect its exposure or contribute to overlapping adverse reactions.
Before prescribing alectinib, healthcare professionals should review:
- Prescription medicines.
- Non-prescription medicines.
- Medicines affecting heart rate.
- Other anticancer treatments.
- Vitamins and supplements.
- Herbal preparations.
Patients should not start or discontinue medicines without consulting their doctor or pharmacist.
11. Use in Specific Populations
Pregnancy
Alectinib may cause fetal harm. Pregnant patients should discuss treatment risks and alternatives with their oncologist.
Breastfeeding
Breastfeeding is not recommended during treatment with reference Alecensa under its United States prescribing information.
Older adults
Treatment decisions should consider general health, other medical conditions, concurrent medicines, and treatment tolerance.
Pediatric patients
The safety and effectiveness of reference Alecensa have not been established in pediatric patients under its United States prescribing information.
Patients with kidney impairment
The severity of renal impairment should be assessed before and during treatment. Severe renal toxicity may require treatment modification.
Patients with liver impairment
The reference United States prescribing information recommends 450 mg twice daily for patients with severe hepatic impairment classified as Child-Pugh C. This is a reference-product instruction, not an automatic recommendation for Alecnib.
12. Monitoring Requirements
Regular monitoring helps healthcare professionals identify adverse reactions and evaluate treatment tolerance.
| Monitoring parameter | Reference monitoring guidance |
|---|---|
| ALT, AST, and total bilirubin | Every two weeks for three months, then monthly and as clinically indicated |
| CPK | Every two weeks during the first month and when muscle symptoms occur |
| Heart rate | Regularly |
| Blood pressure | Regularly |
| Triglycerides | Before treatment and periodically |
| Kidney function | As clinically indicated |
| Respiratory symptoms | Prompt assessment if new or worsening symptoms develop |
| Cancer response | Clinical and imaging assessments as appropriate |
The treating oncologist may adjust monitoring according to the patient’s condition.
13. Overdose Information
An overdose of alectinib may increase the risk of adverse reactions.
If a patient takes more than the prescribed amount, they should promptly contact a healthcare professional or local poison information service.
Do not wait for symptoms to develop before seeking advice. Severe symptoms require emergency medical assessment.
There is no reason to assume that an additional dose will improve treatment effectiveness.
14. Storage and Handling
Storage instructions should be taken from the specific Alecnib packaging and manufacturer documentation.
General precautions include:
- Keep the medicine in its original packaging when appropriate.
- Follow the stated storage temperature.
- Protect the medicine from unsuitable environmental conditions.
- Keep it away from children.
- Check the expiry date before use.
- Do not use damaged or expired medicine.
- Ask a pharmacist about safe disposal.
15. Patient Counseling Information
Patients receiving alectinib should understand the importance of following the prescribed treatment schedule and reporting concerning symptoms.
Healthcare professionals should explain:
- The reason for treatment.
- The importance of ALK testing.
- The prescribed dosage and administration schedule.
- Food requirements for the applicable formulation.
- Instructions for missed doses and vomiting.
- Possible adverse reactions.
- Required laboratory tests.
- Pregnancy and breastfeeding precautions.
- Potential medicine interactions.
- When urgent medical attention is necessary.
Patients should be encouraged to maintain regular follow-up appointments and communicate any treatment difficulties to their healthcare team.
16. Important Information About Alecnib Product Verification
The information on this page describes alectinib and includes selected prescribing information from the United States reference product Alecensa.
It does not independently establish that Alecnib:
- Has the same regulatory authorization as Alecensa.
- Is manufactured by the same company.
- Has an identical formulation.
- Has been approved for the same indications.
- Has identical product-specific instructions.
- Is interchangeable with another alectinib product.
Before prescribing or dispensing Alecnib, healthcare professionals should verify its actual manufacturer, product registration, formulation, strength, and applicable prescribing documentation.
Important Prescribing Disclaimer
This page is an educational summary and is not an official package insert, approved product label, or substitute for professional prescribing documentation.
The dosing, indications, and safety information identified as reference information are based on the United States prescribing information for Alecensa revised in August 2026. Local approvals and prescribing requirements may differ.
Alecnib 150 mg must not be prescribed or used solely on the basis of this webpage. Healthcare professionals should consult the applicable official product documentation and exercise independent clinical judgment. Patients should use alectinib only under the supervision of a qualified oncologist.